L-Isoleucine: A Comprehensive Reference
1. Identity and Chemical Characterization
L-Isoleucine is a proteinogenic, essential α-amino acid. Its IUPAC name is (2S,3S)-2-amino-3-methylpentanoic acid, and it is identified by Chemical Abstracts Service (CAS) number 73-32-5, with an EINECS number of 200-798-2. Its molecular mass is 131.17 g/mol and its chemical formula is C6H13NO2.
The standard one-letter abbreviation for isoleucine is I, and the three-letter abbreviation is Ile. Isoleucine is one of the three branched-chain amino acids (BCAAs), alongside leucine and valine. Isoleucine is characterized by its hydrophobic side chain consisting of a methyl group attached to a carbon that is part of a larger hydrocarbon chain — a structure responsible for its unique physical and chemical properties, particularly its role in protein folding and stability.
Four stereoisomers of isoleucine are theoretically possible, including two diastereomers of L-isoleucine. However, the isoleucine present in nature exists in only one specific form, (2S,3S)-2-amino-3-methylpentanoic acid, and only this form is involved in the synthesis of proteins. In its purified supplement form, L-isoleucine appears as a white crystalline powder with a characteristic smell, and is slightly soluble in water and nearly insoluble in organic solvents such as ethanol and ether. It has a melting point of 284 °C and a molecular weight of 131.17 g/mol.
The isoelectric point of L-isoleucine is approximately 6.02, at which point it has the lowest solubility in solution, is electrically neutral, and is most likely to precipitate. As an L-type amino acid, it has optical activity and can rotate plane-polarized light, which is one of the key characteristics that distinguishes it from the D-type isomer.
Natural Sources
Rich dietary sources of isoleucine include eggs, chicken, pork, mutton, pulses, soybeans, cottage cheese, milk, piyal seeds, cashew nuts, and cereal grains. While isoleucine is not synthesized in animals, in plants and microorganisms it is synthesized via several biosynthetic steps starting from pyruvic acid.
Common Forms and Preparations
Isoleucine can be supplemented individually but is more commonly taken as part of a BCAA or complete protein supplement — for example, whey protein or soy protein. In commercial supplement production, L-isoleucine is produced by fermentation using bacterial strains such as Corynebacterium glutamicum, and the resulting product is considered an efficacious source of the essential amino acid for non-ruminant animal species. By specification, commercial supplement-grade L-isoleucine typically contains ≥90% L-isoleucine on an "as is" basis, with ≤2% moisture and ≤1% ash.
2. Traditional and Historical Use
L-Isoleucine, as a discrete isolated compound, is a product of modern biochemistry and was not used as a purified ingredient in traditional medicine systems. Isoleucine has been recognized as an essential nutrient since its discovery in the early 20th century. Before its isolation and characterization, its effects were experienced exclusively through dietary protein intake.
Historically, isoleucine has been used in medical nutrition formulas and sports supplements, reflecting its role in protein synthesis, energy production, and muscle metabolism, and scientific validation for its use has emerged through both animal and human studies. Isoleucine-rich foods and preparations — such as legumes, seeds, and whole grains — were central to dietary interventions in traditional cultures for strength, endurance, and recovery.
The isolated amino acid's application as a clinical and sports-nutrition supplement began in earnest in the latter decades of the 20th century. Athletes and bodybuilders have utilized isoleucine supplements to enhance muscle recovery and performance, making it a staple in sports nutrition. L-isoleucine has been recognized principally as a material for various drugs, represented by medicines for promoting nutrition.
3. Key Constituents, Biochemistry, and Mechanisms of Action
Essential Amino Acid Status and BCAA Classification
As an essential amino acid, isoleucine must be obtained from external sources — either through diet or supplements — because the human body cannot synthesize it naturally. The BCAAs (leucine, isoleucine, and valine) are essential amino acids that must be obtained from the diet, and not only act as building blocks for tissue protein (accounting for approximately 35% of the essential amino acids in muscle) but also have other metabolic functions.
Metabolic Fate: Glucogenic and Ketogenic Dual Character
The catabolism of isoleucine ultimately yields acetyl-CoA and propionyl-CoA, making isoleucine both glucogenic and ketogenic. More specifically, after transamination with alpha-ketoglutarate, the carbon skeleton is oxidized and split into propionyl-CoA and acetyl-CoA. As a branched-chain amino acid, isoleucine is metabolized primarily by peripheral tissues such as muscle, rather than the liver; catabolism involves transamination, oxidative decarboxylation, and a dehydrogenase step catalyzed by a vitamin B6-requiring enzyme, branched-chain α-amino acid aminotransferase.
Protein Synthesis and the mTOR Pathway
As one of the three BCAAs, a primary function of isoleucine is its involvement in muscle protein synthesis, as it stimulates the mTOR signaling pathway, which is essential for muscle growth and repair. However, the specific contributions of the three BCAAs to mTOR signaling differ importantly: of the BCAAs, leucine appears to be the specific effector on protein synthesis in several tissues including skeletal muscle, liver, and adipose tissue, with its stimulatory effect occurring at the level of translation initiation through the mammalian target of rapamycin (mTOR); of the BCAAs, only leucine is a key regulator of protein synthesis via the mTOR pathway. Leucine is the most potent of the BCAAs in stimulating muscle protein synthesis, while isoleucine and valine are much less effective.
Glucose Transport and Insulin-Independent Glucose Uptake
Among novel BCAA functions, BCAAs — especially isoleucine — play a major role in enhancing glucose consumption and utilization by up-regulating intestinal and muscular glucose transporters. Isoleucine administration stimulates both glucose uptake in the muscle and whole body glucose oxidation, in addition to depressing gluconeogenesis in the liver, thereby leading to a hypoglycemic effect in rats. Key mechanistic details from rat studies: oral administration of isoleucine decreased plasma glucose levels by 20% and significantly increased muscle glucose uptake by 71% without significant elevation of the plasma insulin level compared with controls at 60 minutes after administration.
Hemoglobin Formation
Fetal hemoglobin is one of the many proteins that require isoleucine; isoleucine is present in the gamma chain of fetal hemoglobin and must be present for the protein to form. Isoleucine also plays an important role in immune function, hemoglobin production, and the detoxification of nitrogenous waste.
Innate Immune Defense: Induction of Antimicrobial Peptides
Supplementation with L-isoleucine has been postulated to induce antimicrobial peptides in the intestine that have activities against enteric bacteria and viruses; antimicrobial peptides represent an important component of innate immune defenses and are broad-spectrum surface-acting agents secreted by epithelial cells in response to infection. Recently, L-isoleucine and its analogues have been found to induce these antimicrobial peptides.
Inflammation and Intestinal Barrier
In animal studies, dietary L-isoleucine supplementation has been shown to attenuate the negative effects of DSS-induced colitis on growth performance, disease activity index, colonic length, and enterocyte apoptosis, while downregulating the ratio of inflammatory immune cells, pro-inflammation cytokines, and the mRNA expression of TLR4, MyD88, and NF-κB in the colon. These findings are primarily from rodent models and have not yet been replicated in large human clinical trials.
4. Scientific Evidence by Area of Use
4.1 Muscle Recovery, Exercise Performance, and Body Composition
BCAAs are an increasingly popular sports supplement used by athletes as they are advertised to increase endurance, muscle recovery, lean muscle mass, and decrease muscle soreness and fatigue; however, the mechanisms behind BCAAs are not well-established, and previous studies have had mostly equivocal results, making the possible performance-enhancing effect controversial.
A systematic review published in PMC conducted a comprehensive search of the literature through 2025. From 2,298 records found, 24 studies met the inclusion criteria. Although BCAAs tended to activate anabolic signals, the benefits on performance and body composition were negligible. Studies that included resistance-trained participants showed that BCAAs attenuated muscle soreness after exercise, while in endurance sports the findings were inconsistent. The protocols of BCAA supplements differed considerably between studies; moreover, most studies did not report total protein intake across the day, and consequently the benefits of BCAAs should be interpreted with caution.
A six-month randomized controlled trial examining sex-based differences in BCAA supplementation and resistance training found specific results: subjects in the BCAA group took five daily capsules of 500 mg L-leucine, 250 mg L-isoleucine, and 250 mg L-valine for six months. Notable findings included significant improvements in muscle recovery, as indicated by reduced delayed-onset muscle soreness (DOMS), particularly in women (reduction of 18.1 ± 9.4 mm on a 100 mm visual analogue scale compared to 0.8 ± 1.2 mm in placebo); fatigue perception was also significantly lower in the BCAA group; strength gains were prominent especially in men, with a 10% increase in bench press maximum in the BCAA group; the interaction between sex and treatment was significant, suggesting sex-specific responses to BCAA supplementation.
A pilot randomized controlled trial in older adults examined the effects of BCAAs combined with exercise: BCAAs — leucine, isoleucine, and valine — are essential amino acids that play a key role in muscle protein synthesis, with a standardized 2:1:1 leucine:isoleucine:valine ratio commonly used in research and commercial products, and effective doses ranging from 77 to 100 mg/kg body weight per day. This pilot randomized, double-blind, placebo-controlled trial examined the impact of BCAA supplementation combined with exercise on physical and mental fatigue, physical performance, and self-reported quality of life in fatigued older adults, assessing both acute (single-dose) and longer-term (8-week) effects to provide preliminary evidence on feasibility, safety, and potential efficacy.
Evidence strength: The evidence for BCAA supplementation (including isoleucine as a component) on muscle soreness reduction is moderate and reasonably consistent across several randomized trials. Evidence for improvements in exercise performance and body composition is weak and inconsistent. Isoleucine-specific (isolated) trials on exercise performance are lacking.
4.2 Blood Glucose Regulation and Metabolic Health
Isoleucine has a regulatory effect on glucose transport and metabolism in the body and has been suggested to have a hypoglycemic (blood sugar-lowering) effect when taken before glucose/carbohydrates; while this has been observed in animals, human clinical trials so far have shown more limited results.
A clinical trial published in ScienceDirect administered isoleucine with and without glucose in non-diabetic subjects: in healthy subjects, both leucine and isoleucine reduced blood glucose in response to a mixed-nutrient drink but did not affect subsequent energy intake; the mechanisms underlying glucose lowering appear to differ — leucine stimulated insulin secretion, whereas isoleucine acted insulin-independently.
A published study in The Journal of Nutrition confirmed that isoleucine prevents a rise in plasma glucose concentration in an oral glucose tolerance test in normal rats, with an effect greater than that of leucine or valine. Isoleucine lowered blood glucose and stimulated glucose uptake in rat skeletal muscle in vivo without increasing plasma insulin, indicating that, compared with an amino acid mixture, isoleucine has a distinctly different effect on glucose metabolism.
However, there is important complexity and conflicting data in this area. Paradoxically, epidemiologic studies also show that higher levels of plasma BCAAs have been linked to insulin resistance and type 2 diabetes. Elevated fasting BCAAs correlate with insulin resistance risk; intervention data are evolving and emphasize overall diet, weight, and physical activity as dominant levers.
In rat studies, dosages of 0.3–0.45 mg/kg were effective for reducing blood glucose and increasing muscle cell glucose uptake, which could be extrapolated to a human dose of 48–72 mg/kg (3.3–4.9 g for a 150 lb person), but these beneficial effects have not yet been clearly established in clinical trials.
Evidence strength: Mechanistic evidence for insulin-independent glucose uptake is robust in animal and in vitro models. Evidence from human trials is preliminary and limited. The epidemiological association of elevated BCAAs with insulin resistance and type 2 diabetes introduces important uncertainty about the long-term metabolic effects of high supplemental BCAA intake.
4.3 Immune Function and Antimicrobial Defense
A double-blind, randomized controlled trial investigated L-isoleucine-supplemented oral rehydration solution (ORS) in children with acute diarrhoea: the objective was to examine if addition of L-isoleucine to ORS solution would reduce stool output and/or duration of acute diarrhoea in children and induce antimicrobial peptides in the intestine; the trial was conducted at the Dhaka Hospital of ICDDR,B; fifty male children, aged 6–36 months, with acute diarrhoea and some dehydration were included; 25 children received L-isoleucine (2 g/L)-added ORS (study group) and 25 received ORS without L-isoleucine (control). Results indicated that human beta-defensin-3 (HBD-3) exhibited an increase in stool concentrations in the treatment group.
In animal models, dietary L-isoleucine supplementation attenuated diarrhea and decreased growth impairment, decreased NSP4 concentration in ileal mucosa, and enhanced the production and/or expression of immunoglobulins, rotavirus antibody, cytokines, and beta-defensins in serum, ileum, and/or mesenteric lymph nodes of weaned piglets; these results indicate that dietary L-isoleucine can improve immune function via activation of the pattern-recognition receptor (PRR) signaling pathway in rotavirus-infected piglets.
BCAAs participate in up-regulating innate and adaptive immune responses. Due to being highly incorporated into immune cells and increasing the expression of host defense peptides, isoleucine is considered critical for the function of the immune system.
Evidence strength: The evidence from animal models and in vitro studies is compelling and mechanistically plausible. Human data are limited to small proof-of-concept trials (notably the ICDDR,B paediatric RCT). Large-scale human clinical trials confirming immune benefits of standalone L-isoleucine supplementation are not yet available.
4.4 Intestinal Health and Inflammatory Bowel Conditions
Animal research has shown that L-isoleucine can modulate gut inflammation. Dietary L-isoleucine supplementation in a rat model of DSS-induced colitis downregulated pro-inflammation cytokines and the mRNA expression of TLR4, MyD88, and NF-κB in the colon, while attenuating disruptions to growth performance, disease activity, and colonic integrity.
BCAAs have been found to enhance intestinal development, intestinal amino acid transportation, and mucin production.
Evidence strength: Currently animal/in vitro only. No established human clinical evidence for isoleucine in inflammatory bowel disease or intestinal permeability disorders exists.
4.5 Aging, Sarcopenia, and Older Adults
A metabolomics study showed that isoleucine and leucine levels decreased in the blood of aged human subjects. The increased susceptibility of older adults to exercise-induced muscle damage and delayed recovery has led to interest in complementary nutritional strategies such as BCAAs to enhance recovery and address both physical and mental fatigue.
BCAAs are rapidly absorbed and may be better tolerated by older adults compared to whole protein or multi-nutrient supplements, allowing for targeted delivery of anabolic amino acids.
Evidence strength: Preliminary evidence from pilot RCTs. The decline of BCAAs including isoleucine with aging provides a theoretical basis for supplementation in sarcopenia; controlled long-term trials are needed.
5. Body Systems and Health Areas Associated with L-Isoleucine
- Musculoskeletal system: As a BCAA, isoleucine plays a particularly important role in muscle tissue repair, lean mass preservation, and protein synthesis.
- Metabolic/endocrine system: Isoleucine exerts a positive influence on insulin sensitivity and glucose metabolism, thereby promoting metabolic health.
- Hematological system: Fetal hemoglobin requires isoleucine; it is present in the gamma chain of fetal hemoglobin and must be present for the protein to form.
- Immune system: Isoleucine can enhance immune function.
- Gastrointestinal system: BCAAs enhance intestinal development, intestinal amino acid transportation, and mucin production.
- Energy metabolism: Isoleucine is both glucogenic and ketogenic, meaning it can be metabolized into either glucose or ketone bodies.
- Detoxification: Isoleucine plays an important metabolic role in detoxifying nitrogenous waste, especially ammonia.
6. Dosage Forms and Dosages Reported in Studies
L-isoleucine is available as a standalone free-form amino acid supplement in capsule, tablet, and powder forms, and as a component of BCAA blends and essential amino acid (EAA) formulas.
- A standardized 2:1:1 leucine:isoleucine:valine ratio is commonly used in research and commercial products, with effective doses ranging from 77 to 100 mg/kg body weight per day.
- In a six-month RCT on strength training and body composition, the BCAA group took five daily capsules of 500 mg L-leucine, 250 mg L-isoleucine, and 250 mg L-valine.
- In the paediatric oral rehydration trial, L-isoleucine was administered at a concentration of 2 g/L in the ORS solution.
- In rat studies, dosages of 0.3–0.45 mg/kg were effective for reducing blood glucose and increasing muscle glucose uptake; extrapolation to humans suggests 48–72 mg/kg (approximately 3.3–4.9 g for a 150 lb person), but these effects have not been clearly established in clinical trials.
There is currently no strong evidence to support the use of isoleucine as a supplement alone and no well-established dosing for standalone supplementation.
7. Safety Considerations and Interactions
General Safety
The EFSA FEEDAP Panel concluded that L-isoleucine produced by fermentation is safe for the target species, consumers, and the environment when used as a nutritional additive in feed. L-isoleucine is not irritant to skin and eyes and is not a dermal sensitizer, but is considered hazardous by inhalation (relevant for dust exposure in industrial settings).
Nutritional Imbalance Risk
The EFSA FEEDAP Panel reiterates concerns over the safety of L-isoleucine administered simultaneously via water for drinking and feed, owing to the risk of nutritional imbalances. Abnormally elevated BCAA levels in the blood (resulting from decreased BCAA catabolism) are a good biomarker for the early detection of obesity, diabetes, and other metabolic diseases.
Maple Syrup Urine Disease (MSUD)
Maple syrup urine disease (MSUD) is a rare genetic disorder characterized by deficiency of the branched-chain alpha-keto acid dehydrogenase complex, which is required to metabolize all three BCAAs; the result is that all three BCAAs, along with a number of toxic byproducts (their respective organic acids), accumulate abnormally. Paradoxically, isoleucine plays a dual role in MSUD: individuals with this condition cannot tolerate elevated levels of any BCAA, yet they are also at risk of isoleucine deficiency from dietary restriction.
A clinical case of MSUD during diet therapy presented a picture with predominant cutaneous symptoms attributed to dietary deficiency, believed to be caused by coexistence of low serum isoleucine levels with still-elevated leucine levels; given the metabolic interrelationship between different branched-chain amino acids, independent dietary correction of each amino acid is recommended.
In MSUD, the appearance of cutaneous lesions is likely related to isoleucine deficiency, which can interfere with protein synthesis essential for keratinocyte metabolism. Correction of isoleucine deficiency and leucine restriction led to complete resolution of skin eruption by 4 weeks, correlating with normalization of BCAA levels.
Protein Amino Acid Interactions
Various studies showed that elevations of plasma amino acids after administration of an amino acid mixture induce insulin resistance in skeletal muscle — the so-called amino acid-induced insulin resistance — by inhibiting glucose transport and glucose phosphorylation in humans. Isoleucine given in isolation appears to behave differently from amino acid mixtures with respect to glucose metabolism.
Ruminant Considerations
For supplemental L-isoleucine to be as efficacious in ruminants as in non-ruminant species, it requires protection against degradation in the rumen.
Amino Acid Catabolism and Excretion
Amino acids cannot be stored in the body; buildup of excess amino acids will cause a buildup of toxic molecules, and humans have many metabolic pathways to degrade each amino acid when the need for protein synthesis has been met.
8. Evidence Gaps and Research Limitations
Standalone isoleucine in humans is promising for postprandial glucose modulation, but dose-finding and long-term trials in diverse populations are limited. Key research gaps include dose-response trials of isoleucine alone in humans for glucose, performance, and recovery endpoints; comparisons of EAA vs. BCAA vs. complete protein supplements under matched protein totals; and long-term safety data for chronic high BCAA intakes in different metabolic phenotypes.
Although animal studies suggest isoleucine could have a beneficial effect on blood sugar regulation, energy metabolism, and diabetes, evidence in humans is mixed. The majority of mechanistic findings — including the glucose-lowering, immune-modulating, and intestinal protective effects described in the literature — derive from in vitro cell culture experiments or animal models, and direct translation to human therapeutic benefit remains to be confirmed by adequately powered, well-controlled clinical trials.
References
Go back